Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Aytu BioScience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications. Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS).
Brand Name : AR101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 12, 2021
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Aytu BioScience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?